Search
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalof both primary and secondary MF in patients with platelet counts < 50 x 10<sup>9</sup>/L. … [L40754] It provides a treatment option for patients who have MF with severe thrombocytopenia, which occurs in approximately one-third of MF patients and carries with it a particularly poor prognosis.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[L24474] It is an agonist of the melanocortin 4 receptor. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor AgonistsMisonidazole
go.drugbank.com/drugs/DB11716InvestigationalMisonidazole is under investigation in clinical trial NCT00038038 (Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole).
Categories: Heterocyclic Compounds, 1-RingEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: BRAFTOVI® 75 MG CÁPSULASMitoglitazone
go.drugbank.com/drugs/DB11721InvestigationalMitoglitazone has been used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.
Categories: Heterocyclic Compounds, 1-RingEncenicline
go.drugbank.com/drugs/DB11726InvestigationalEncenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Categories: Heterocyclic Compounds, 1-RingIcotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalVonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H<sup>+</sup>, K<sup>+</sup>-ATPase-mediated gastric acid secretion. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineAdavosertib
go.drugbank.com/drugs/DB11740InvestigationalMK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
Categories: Heterocyclic Compounds, 1-RingEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: EVASTEL Z, PINAVALT® SOLUCION